Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor α

The cyclic peptide AF17121 (Ac‐VDECWRIIASHTWFCAEE) that inhibits interleukin 5 (IL‐5) function and IL‐5 receptor α‐chain (IL‐5Rα) binding has been derived from recombinant random peptide library screening and follow‐up synthetic variation. To better understand the structural basis of its antagonist activity, AF17121 and a series of analogs of the parent peptide were prepared by solid phase peptide synthesis. Sequence variation was focused on the charged residues Asp2, Glu3, Arg6, Glu17, and Glu18. Two of those residues, Glu3 and Arg6, form an EXXR motif that was found to be common among library‐derived IL‐5 antagonists. The E and R in the EXXR motif have a proximity similar to charged residues in a previously identified receptor α binding region, the β‐strand between the C‐ and D‐helices of human IL‐5. Optical biosensor interaction kinetics and cell proliferation assays were used to evaluate the antagonist activities of the purified synthetic peptides, by measuring competition with the highly active single chain IL‐5. Analogs in which acidic residues (Asp2, Glu3, Glu17, and Glu18) were replaced individually by Ala retained substantial competition activity, with multiple replacements in these residues leading to fractional loss of potency at most. In contrast, R6A analogs had strongly reduced competition activity. The results reveal that the arginine residue is crucial for the IL‐5Rα binding of AF17121, while the acidic residues are not essential though likely complex‐stabilizing particularly in the Asp2–Glu3 region. By CD, AF17121 exhibited mostly disordered structure with evidence for a small β‐sheet content, and replacement of the arginine had no influence on the observed secondary structure of the peptides. The dominance of Arg6 in AF17121 activity corresponds to previous findings of dominance of the positive charge balance in the antiparallel β‐sheet of IL‐5 composed of 88EERRR92 in one strand of the CD turn region of IL‐5 and with Arg32 in the neighboring β‐strand. These results argue that AF17121 and related library‐derived peptides function by mimicking the CD turn receptor α recognition epitope in IL‐5 and open the way to small molecule antagonist design. © 2004 Wiley Periodicals, Inc. Biopolymers, 2004

[1]  N. Skelton,et al.  Amino acid determinants of beta-hairpin conformation in erythropoeitin receptor agonist peptides derived from a phage display library. , 2002, Journal of molecular biology.

[2]  J. Tavernier,et al.  A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific α chain and a β chain shared with the receptor for GM-CSF , 1991, Cell.

[3]  C. Pace,et al.  How to measure and predict the molar absorption coefficient of a protein , 1995, Protein science : a publication of the Protein Society.

[4]  I. Wilson,et al.  Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.

[5]  A. Beresford,et al.  Modified peptide antagonists of interleukin 5 exhibit extended in vivo persistence but restricted species specificity. , 2001, Cytokine.

[6]  M. Migita,et al.  Molecular cloning and expression of the human interleukin 5 receptor , 1992, The Journal of experimental medicine.

[7]  V. Mordvinov,et al.  Biological and molecular characteristics of interleukin-5 and its receptor. , 1998, International reviews of immunology.

[8]  M. Doyle,et al.  Monomeric isomers of human interleukin 5 show that 1:1 receptor recruitment is sufficient for function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Vadas,et al.  GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells. , 1992, Immunology today.

[10]  I. Chaiken,et al.  Coiled coil miniprotein randomization on phage leads to charge pattern mimicry of the receptor recognition determinant of interleukin 5 , 2002, Journal of molecular recognition : JMR.

[11]  Nicos Nicola,et al.  Guidebook to cytokines and their receptors , 1994 .

[12]  R. Woody Chapter 2 – Circular Dichroism of Peptides , 1985 .

[13]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[14]  M. Lambert,et al.  A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5 , 1993, Nature.

[15]  Rabindra Tambyraja,et al.  Epitope Randomization Redefines the Functional Role of Glutamic Acid 110 in Interleukin-5 Receptor Activation* , 2000, The Journal of Biological Chemistry.

[16]  Emma Evergren,et al.  Biosensor analysis of dynamics of interleukin 5 receptor subunit βc interaction with IL5:IL5Rα complexes , 2002 .

[17]  C. Sanderson Interleukin-5: From Molecule to Drug Target for Asthma , 1998 .

[18]  G. Fasman,et al.  Computed circular dichroism spectra for the evaluation of protein conformation. , 1969, Biochemistry.

[19]  N. Greenfield Methods to estimate the conformation of proteins and polypeptides from circular dichroism data. , 1996, Analytical biochemistry.

[20]  J. Tavernier,et al.  Recombinant soluble human interleukin-5 (hIL-5) receptor molecules. Cross-linking and stoichiometry of binding to IL-5. , 1993, The Journal of biological chemistry.

[21]  E. Whitehorn,et al.  A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor alpha chains. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Peitsch,et al.  Identification of Key Charged Residues of Human Interleukin-5 in Receptor Binding and Cellular Activation (*) , 1995, The Journal of Biological Chemistry.

[23]  I. Chaiken,et al.  Multisite mutagenesis of interleukin 5 differentiates sites for receptor recognition and receptor activation. , 2000, Biochemistry.

[24]  S. Carr,et al.  Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins. , 1995, The Journal of biological chemistry.

[25]  J. Tavernier,et al.  Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Fasman,et al.  Conformational analysis of pseudocyclic hexapeptides based on quantitative circular dichroism (CD), NOE, and x-ray data. The pure CD spectra of type I and type II .beta.-turns , 1991 .

[27]  G. Fasman,et al.  Quantitative analysis of cyclic β‐turn models , 1992, Protein science : a publication of the Protein Society.

[28]  I. Chaiken,et al.  Single Chain Human Interleukin 5 and Its Asymmetric Mutagenesis for Mapping Receptor Binding Sites (*) , 1996, The Journal of Biological Chemistry.

[29]  R. Cook,et al.  Mutants of Single Chain Interleukin 5 Show Asymmetric Recruitment of Receptor α and βc Subunits* , 1996, The Journal of Biological Chemistry.

[30]  G Canziani,et al.  Randomization of the Receptor α Chain Recruitment Epitope Reveals a Functional Interleukin-5 with Charge Depletion in the CD Loop* , 1999, The Journal of Biological Chemistry.

[31]  R. Cook,et al.  Mutagenesis in the C-terminal region of human interleukin 5 reveals a central patch for receptor alpha chain recognition. , 1995, Proceedings of the National Academy of Sciences of the United States of America.